Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Large granular lymphocyte (LGL) leukemia is characterized by the expansion of antigen-activated cytotoxic T lymphocytes. These leukemic cells are resistant to Fas-mediated apoptosis despite expressing high levels of Fas. We found that leukemic LGL from 19 patients displayed high levels of activated STAT3. Treatment of leukemic LGL with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity. Moreover, using an antisense oligonucleotide approach to diminish STAT3 expression, we found that Fas sensitivity was restored in leukemic LGL. AG-490-induced apoptosis in leukemic LGL was independent of Bcl-xL or Bcl-2 expression. However, we found that the Bcl-2-family protein Mcl-1 was significantly reduced by AG-490 treatment. Activated STAT3 was shown to bind an SIE-related element in the murine mcl-1 promoter. Using a luciferase reporter assay, we demonstrated that v-src overexpression in NIH3T3 induced STAT3-dependent transcriptional activity from the mcl-1 promoter and increased endogenous Mcl-1 protein levels. We conclude that STAT3 activation contributed to accumulation of the leukemic LGL clones. These findings suggest that investigation should focus on novel strategies targeting STAT3 in the treatment of LGL leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibition strategies include the introduction of antisense oligonucleotides, as in the case of the Isis Pharmaceuticals, Inc/AstraZeneca drug in clinical development, designed to cause degradation of STAT3 mRNA or prevent its translation via complementary base pairing, thereby reducing total STAT3 protein levels.105”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the STAT3 protein in the peripheral blood mononuclear cell extracts isolated from patients with large granular lymphocyte leukemia has been reported to bind to the murine SIE motif (9).”
The cited source says what the claim attributes to it.
In the citing paper
“IL-6 plays a significant role in inducing tumor growth as it interacts with the receptor, JAK, to induce STAT-3 activation. STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30). These activities result in the induction of cancer cell proliferation.”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979 · cited 2×
“Proteolytic cleavage and activation of a cascade of caspases (death proteases) mediate the cleavage of cellular targets, resulting in programmed cell death (38, 39).”
BackgroundLymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationGeneralized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 11×
“Transfection of the indicated plasmids into NIH3T3 cells was performed using CaP04, as described previously (28). pM-v-src and pSG5-STAT3β are plasmid vectors expressing v-src and a dominant negative mutant of STAT3, respectively.”
MethodInfluentialSelf-citationInhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897 · cited 2×
“Therefore, we used a tyrphostin inhibitor (AG-490) selective for the JAKfamily tyrosine kinases to determine whether inhibition of the pathway upstream of STAT activation would affect apoptosis in LGL leukemia cells (32).”
MethodWakao, H., Gouilleux, F., & Groner, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06495.x · Cited by 826 · cited 2×
“The degree of binding was determined by electrophoretic analysis on a 5% native polyacrylamide gel as described previously (19, 31).”
BackgroundMethodLin, J.-X., Migone, T.-S., Tseng, M., Friedmann, M., Weatherbee, J. A., Zhou, L., Yamauchi, A., Bloom, E. T., Mietz, J., John, S., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90141-8 · Cited by 752 · cited 2×
“In agreement with previously reported data, little or no SIE-DNA–binding activity was detected with nuclear extracts derived from five normal donors (Figure 1a, lanes 1–5) (36).”
BackgroundInvolvement of an ICE-like protease in Fas-mediated apoptosis
Enari, M., Hug, H., & Nagata, S. (1995) · Nature · doi:10.1038/375078a0 · Cited by 734 · cited 2×
“Proteolytic cleavage and activation of a cascade of caspases (death proteases) mediate the cleavage of cellular targets, resulting in programmed cell death (38, 39).”
BackgroundClonal diseases of large granular lymphocytes [see comments]
Loughran, T. J. (1993) · Blood · doi:10.1182/blood.v82.1.1.bloodjournal8211 · Cited by 697 · cited 4×
“STAT3 regulates the growth and immunoglobulin production of BCL (1) B cell lymphoma through control of cell cycle progression.”
BackgroundInfluentialSelf-citationStat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation
Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., & Jove, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2545 · Cited by 651 · cited 2×
“As demonstrated previously, the pLucSRE was inducible by v-src overexpression, but no inhibition was observed by coexpression of STAT3β (28).”
BackgroundMethodSelf-citationStat3 Activation Is Required for Cellular Transformation by v- src
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., & Darnell, J. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2553 · Cited by 614
The SIF binding element confers sis/PDGF inducibility onto the c‐fos promoter.
Wagner, B. J., Hayes, T. E., Hoban, C. J., & Cochran, B. H. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07898.x · Cited by 592 · cited 3×
“STAT3 and STAT1 control bcl-x transcription (9, 42).”
MethodGrandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., & Tweardy, D. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3785 · Cited by 507
Garcia, R., Yu, C., Hudnall, A. M., Catlett, R., Nelson, K. L., Smithgall, T. E., Fujita, D. J., Ethier, S. P., & Jove, R. (1997) · PubMed · Cited by 441
Self-citationSeidel, H. M., Milocco, L. H., Lamb, P., Darnell, J. E., Stein, R. B., & Rosen, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.3041 · Cited by 415
Hsu, S. Y., Kaipia, A., McGee, E., Lomeli, M., & Hsueh, A. J. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12401 · Cited by 370
Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse
Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., & Reed, J. C. (1998) · Blood · doi:10.1182/blood.v91.3.991 · Cited by 365 · cited 1×
“It was also shown that elevation in Mcl-1 protein expression correlated with relapse in acute leukemias (50).”
BackgroundWang, J.-M., Chao, J.-R., Chen, W., Kuo, M.-L., Yen, J. J.-Y., & Yang-Yen, H.-F. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6195 · Cited by 357 · cited 5×
“The mcl-1 gene was recently demonstrated to be controlled by both PI3K–mediated CRE-2 activation and PI3-K–independent activation of an SIE (STAT3-like) sequence in response to IL-3 and GM-CSF (34, 35).”
BackgroundMethodResultInfluentialSelf-citationThe Roles of Costimulation and Fas in T Cell Apoptosis and Peripheral Tolerance
Van Parijs, L., Ibraghimov, A., & Abbas, A. K. (1996) · Immunity · doi:10.1016/s1074-7613(00)80440-9 · Cited by 351 · cited 2×
“Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3+ large granular lymphocyte leukemia.”
BackgroundThe Lymphoproliferative Disease of Granular Lymphocytes: Updated Criteria for Diagnosis
Semenzato, G., Zambello, R., Starkebaum, G., Oshimi, K., & Loughran, T. P. (1997) · Blood · doi:10.1182/blood.v89.1.256 · Cited by 343 · cited 1×
“The disease is characterized by the expansion of CD3+, CD8+, CD57+ LGLs, with many similarities to antigen-activated cytotoxic T lymphocytes (CTLs) (1, 2).”
BackgroundSelf-citationZhou, P., Qian, L., Kozopas, K. M., & Craig, R. W. (1997) · Blood · doi:10.1182/blood.v89.2.630 · Cited by 326
Jak-STAT Signaling Induced by the v- abl oncogene
Danial, N. N., Pernis, A., & Rothman, P. B. (1995) · Science · doi:10.1126/science.7569929 · Cited by 325
Gouilleux-Gruart, V, Gouilleux, F., Desaint, C., Claisse, J., Capiod, J., Delobel, J., Weber-Nordt, R., Dusanter-Fourt, I., Dreyfus, F., Groner, B., et al. (1996) · Blood · doi:10.1182/blood.v87.5.1692.1692 · Cited by 316 · cited 1×
“The loss of STAT activity with freeze thawing of cells has been described previously (24).”
MethodGreenlund, A. C., Morales, M. O., Viviano, B. L., Yan, H., Krolewski, J., & Schreiber, R. D. (1995) · Immunity · doi:10.1016/1074-7613(95)90012-8 · Cited by 304 · cited 2×
“They are regulated by tyrosine phosphorylation, which leads to homodimerization or heterodimerization with other STAT proteins and translocation to the nucleus (13, 14).”
BackgroundChai, S. K., Nichols, G. L., & Rothman, P. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4720 · Cited by 280
Reynolds, J. E., Yang, T., Lü, Q., Jenkinson, J. D., Zhou, P., Eastman, A. R., & Craig, R. W. (1994) · PubMed · Cited by 240
JAK/STAT signaling by cytokine receptors
Liu, K. D., Gaffen, S. L., & Goldsmith, M. A. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80165-9 · Cited by 234
Kneitz, B., Herrmann, T., Yonehara, S., & Schimpl, A. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250925 · Cited by 229 · cited 2×
“Unlike normal TCR-stimulated T cells, STAT5 was distinctly absent in leukemic LGLs from all but two patients examined (36, 43, 44).”
BackgroundMutagenesis of the BH3 Domain of BAX Identifies Residues Critical for Dimerization and Killing
Wang, K., Gross, A., Waksman, G., & Korsmeyer, S. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.6083 · Cited by 216
Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents
Levitzki, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00066-7 · Cited by 214
Activation of STAT transcription factors in oncogenic tyrosine kinase signaling
Garcia, R., & Jove, R. (1998) · Journal of Biomedical Science · doi:10.1007/bf02258360 · Cited by 202
Self-citationFujio, Y., Kunisada, K., Hirota, H., Yamauchi-Takihara, K., & Kishimoto, T. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119484 · Cited by 200 · cited 1×
“STAT3 and STAT1 control bcl-x transcription (9, 42).”
Chao, J.-R., Wang, J.-M., Lee, S.-F., Peng, H.-W., Lin, Y.-H., Chou, C.-H., Li, J.-C., Huang, H.-M., Chou, C.-K., Kuo, M.-L., et al. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.8.4883 · Cited by 185 · cited 5×
“Rapid degradation of Mcl-1 has been previously linked to the presence of a PEST sequence in the protein (34).”
BackgroundMethodInfluentialSelf-citationSun, W. H., Pabon, C., Alsayed, Y., Huang, P. P., Jandeska, S., Uddin, S., Platanias, L. C., & Rosen, S. T. (1998) · Blood · doi:10.1182/blood.v91.2.570 · Cited by 169
Wang, L. H., Kirken, R. A., Erwin, R. A., Yu, C.-R., & Farrar, W. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.3897 · Cited by 161 · cited 1×
“Recent data has demonstrated that AG-490 inhibits not only the JAK-STAT pathway but also mitogen-activated-protein kinase (MAPK), another well-known pathway involved in cell survival and proliferation (57).”
BackgroundDysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3+ Large Granular Lymphocyte Leukemia
Lamy, T., Liu, J. H., Landowski, T. H., Dalton, W. S., & Loughran, T. P. (1998) · Blood · doi:10.1182/blood.v92.12.4771 · Cited by 153
Self-citationLymphocyte Activation in Health and Disease
Berridge, M. J. (1997) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v17.i2.30 · Cited by 144
Hsueh, A. J. W., Lin, P., & Hsueh, A. J. W. (1998) · Molecular Endocrinology · doi:10.1210/me.12.9.1432 · Cited by 136
STAT5 Interaction with the T Cell Receptor Complex and Stimulation of T Cell Proliferation
Welte, T., Leitenberg, D., Dittel, B. N., al-Ramadi, B. K., Xie, B., Chin, Y. E., Janeway, C. A., Bothwell, A. L. M., Bottomly, K., & Fu, X.-Y. (1999) · Science · doi:10.1126/science.283.5399.222 · Cited by 130 · cited 1×
“STAT5-DNA binding is induced after TCR stimulation of normal T lymphocytes (37).”
BackgroundBesser, D., Bromberg, J. F., Darnell, J. E., & Hanafusa, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1401 · Cited by 123
Interleukin 2 signaling involves the phosphorylation of Stat proteins.
Frank, D. A., Robertson, M. J., Bonni, A., Ritz, J., & Greenberg, M. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7779 · Cited by 113 · cited 1×
“They are regulated by tyrosine phosphorylation, which leads to homodimerization or heterodimerization with other STAT proteins and translocation to the nucleus (13, 14).”
BackgroundWakao, H., Gouilleux, F., & Groner, B. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07064.x · Cited by 90
Interleukin-6 in multiple myeloma and related plasma cell dyscrasias
Treon, S. P., & Anderson, K. C. (1998) · Current Opinion in Hematology · doi:10.1097/00062752-199801000-00008 · Cited by 75 · cited 14×
“However, we failed to detect Bcl-xL protein in leukemic LGL.”
BackgroundInfluentialActivation of STAT3 by the c-Fes Protein-tyrosine Kinase
Nelson, K. L., Rogers, J. A., Bowman, T. L., Jove, R., & Smithgall, T. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.12.7072 · Cited by 74
Self-citationEpitope mapping of HTLV envelope seroreactivity in LGL leukaemia
Loughran, T. P., Hadlock, K. G., Perzova, R., Gentile, T., Yang, Q. K., Foung, S. K. H., & Poiesz, B. J. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00691.x · Cited by 65 · cited 1×
“mately 50% of LGL leukemia patients are reactive to an HTLV envelope protein, suggesting infection with an HTLV-related virus (48, 49).”
BackgroundSelf-citationA Role for Perforin in Activation-Induced Cell Death
Spaner, D., Raju, K., Radvanyi, L. G., Lin, Y., & Miller, R. G. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.6.2655 · Cited by 58 · cited 2×
“Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3+ large granular lymphocyte leukemia.”
BackgroundIFN-α Is a Survival Factor for Human Myeloma Cells and Reduces Dexamethasone-Induced Apoptosis
Ferlin, M., Jourdan, M., Liautard, J., Brochier, J., Rossi, J., & Klein, B. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2692 · Cited by 58
IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis.
Ferlin-Bezombes, M., Jourdan, M. L., Liautard, J., et al. (1998) · PubMed · Cited by 56
Design of Conditionally Active STATs: Insights into STAT Activation and Gene Regulatory Function
Milocco, L. H., Haslam, J. A., Rosen, J., & Seidel, H. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2913 · Cited by 52
Perforin gene expression in granular lymphocyte proliferative disorders
Oshimi, K., Shinkai, Y., Okumura, K., Oshimi, Y., & Mizoguchi, H. (1990) · Blood · doi:10.1182/blood.v75.3.704.704 · Cited by 49 · cited 1×
“For example, characteristic of CTLs, the leukemic cells constitutively express perforin and Fas ligand (FasL) (3).”
BackgroundCytokine signaling for proliferation, survival, and death in hematopoietic cells.
Miyajima, A., Ito, Y., & Kinoshita, T. (1999) · PubMed · Cited by 36
Zambello, R., Trentin, L., Pizzolo, G., Bulian, P., Masciarelli, M., Feruglio, C., Agostini, C., Raimondi, R., Chisesi, T., & Semenzato, G. (1990) · Blood · doi:10.1182/blood.v76.10.2080.2080 · Cited by 31
Karras, J. G., McKay, R. A., Lu, T., Pych, J., Frank, D. A., Rothstein, T. L., & Monia, B. P. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1661 · Cited by 29 · cited 2×
“Oligonucleotides were synthesized using phosphorothioate chemistry, and 2′-O-methoxyethyl modification of the five terminal nucleotides (underlined) was used to increase stability, as described previously (33).”
MethodSelf-citationLoughran, T. J., Aprile, J., & Ruscetti, F. (1990) · Blood · doi:10.1182/blood.v75.4.935.935 · Cited by 16
Self-citationYoon, H. J., Sugamura, K., & Loughran, T. J. (1990) · PubMed · Cited by 11
Self-citationHTLV infection and hematologic malignancies
Loughran, T. P. (1996) · Leukemia Research · doi:10.1016/0145-2126(95)00121-2 · Cited by 7 · cited 1×
“mately 50% of LGL leukemia patients are reactive to an HTLV envelope protein, suggesting infection with an HTLV-related virus (48, 49).”
BackgroundSelf-citation
Research works printed but not linked: 6
- Mayajima, 1999, Int J Hematol, 69, 137
- Garcia, 1997, Cell Growth Diff, 8, 1267
- Yoon, 1990, Leukemia, 4, 848
- Kaufmann, 1998, Blood, 91, 991, 10.1182/blood.v91.3.991.991_991_1000 · doi:10.1182/blood.v91.3.991.991_991_1000 · Paper page
- Reynolds, 1994, Cancer Res, 54, 6348
- Hsu, 1998, Mol Endocrinol, 12, 1432, 10.1210/mend.12.9.0166 · doi:10.1210/mend.12.9.0166 · Paper page
Cited by
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
“Blocking either of these STAT proteins in human tumour cells has been shown to downregulate MCL1 expression and induce tumour-cell apoptosi”
BackgroundSelf-citationCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,165
Buettner, R., Mora, L. B., & Jove, R. (2002) · PubMed · Cited by 1,185
Self-citationDe Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898
Metadata
- Authors
- Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., Jove, R., & Loughran, T. P.
- Affiliations
- University of South Florida (US)
- National Taiwan University (TW)
- Ionis Pharmaceuticals (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 351-362
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC199188
- OpenAlex
- W2041204531
- Cited by
- 633
- References
- 60
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 26 · 2020: 31 · 2019: 22 · 2018: 14 · 2017: 27 · 2016: 15 · 2015: 27 · 2014: 46 · 2013: 31 · 2012: 35
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Moffitt Cancer Center
- National Institutes of Health (5r21ca078724-02)
- National Cancer Institute (R01CA055652, CA-55652, CA78724)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- large granular lymphocyte leukemia, STAT3 signaling, apoptosis, Mcl-1, Fas resistance, AG490, antisense oligonucleotides, Bcl-2 family proteins, v-Src
- MeSH terms
- Cell Line, DNA-Binding Proteins, Enzyme Inhibitors, Gene Expression Regulation, Humans, Leukemia, Neoplasm Proteins, Phosphorylation, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Trans-Activators, Oncogene Protein pp60(v-src), Apoptosis, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins c-bcl-2, Dimerization, Tyrphostins, STAT3 Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.